HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.
June 17, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics and maintained a $20 price target, indicating continued confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. It suggests confidence in Aprea Therapeutics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100